Key facts
- This page summarizes Adele M. Gulfo's Form 4 filing for Myovant Sciences Ltd..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Oct 2022, 16:38.
Adele M. Gulfo - 26 Oct 2022 Form 4 Insider Report for Myovant Sciences Ltd.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 26 Oct 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Oct 2022, 16:38:23 UTC
- Prior SEC filing
- 15 Sep 2022
- Next SEC filing
- 15 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Lang, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adele M. Gulfo filed Form 4 for Myovant Sciences Ltd. on 28 Oct 2022.
Change
- Previous filing in this sequence was filed on 15 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MYOV
transaction
Common Shares
Award
- Transaction value
- $0
- Shares
- +9,859
- Change %
- Price
- $0.000000
- Shares after
- 9,859
- Date
- 26 Oct 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person as the annual non-employee director grant. The RSUs shall (x) vest in full on the earlier to occur of (i) October 26, 2023 and (ii) the date that is one day prior to the Issuer's 2023 annual shareholder meeting, subject in each case to the Reporting Person providing continuous service to the Issuer on such date, or (y) to the extent the RSUs have not vested as of the Effective Time, vest pro rata based on the number of days the Reporting Person has served since October 26, 2022 (by using 365 days for a full year), and the vested RSUs shall be entitled to the RSU Consideration as set forth in Section 2.04(b)(i) of the Merger Agreement, and the unvested RSUs shall be forfeited without consideration as of the Effective Time.
Footnote F2
Each capitalized term not defined above has the meaning assigned to it in that certain Agreement and Plan of Merger by and among the Issuer, Sumitovant Biopharma Ltd., Zeus Sciences Ltd., and, solely with respect to Article IX and Annex A, Sumitomo Pharma Co., Ltd. dated October 23, 2022 (the "Merger Agreement").